Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-024101
Filing Date
2025-08-14
Accepted
2025-08-14 16:45:50
Documents
67
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1071037
2 EX-31.1 ex31-1.htm EX-31.1 11996
3 EX-31.2 ex31-2.htm EX-31.2 12025
4 EX-32.1 ex32-1.htm EX-32.1 5358
5 EX-32.2 ex32-2.htm EX-32.2 5690
6 GRAPHIC form10-q_001.jpg GRAPHIC 6470
  Complete submission text file 0001641172-25-024101.txt   5742407

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tvgn-20250630.xsd EX-101.SCH 39911
8 XBRL CALCULATION FILE tvgn-20250630_cal.xml EX-101.CAL 52138
9 XBRL DEFINITION FILE tvgn-20250630_def.xml EX-101.DEF 257388
10 XBRL LABEL FILE tvgn-20250630_lab.xml EX-101.LAB 393253
11 XBRL PRESENTATION FILE tvgn-20250630_pre.xml EX-101.PRE 337071
69 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 794086
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41002 | Film No.: 251220355
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)